Sacituzumab Tirumotecan Plus Pembrolizumab Demonstrates a Major PFS Benefit in First-Line PD-L1-Negative Advanced NSCLC
OptiTROP-Lung06 (NCT06711900) is a randomized, open-label Phase III study evaluating sac-TMT plus pembrolizumab against standard platinum-based chemotherapy plus pembrolizumab in previously untreated, locally advanced or metastatic non-squamous NSCLC with PD-L1 TPS below 1% and no targetable genomic alterations. A total of 455 patients were randomized to receive sac-TMT plus pembrolizumab (n=229) or chemotherapy plus pembrolizumab (n=226). The primary endpoint was PFS assessed by blinded independent central review (BICR), with OS evaluated as a secondary endpoint. The reported results represent a prespecified interim analysis after a median follow-up of 9.7 months.
|
Key Efficacy and Safety Highlights | |||
|
Category |
Parameter |
Savolitinib + Osimertinib (n=229) |
Placebo + Osimertinib (n=226) |
|
Efficacy |
Median follow-up |
9.7 months |
9.7 months |
|
Median PFS by BICR |
15.0 months |
5.7 months | |
|
PFS hazard ratio |
0.49 |
Comparator arm | |
|
PFS statistical significance |
p<0.001 |
Comparator arm | |
|
PFS rate at 12 months |
51.1% |
22.8% | |
|
Objective response rate |
50.2% |
47.3% | |
|
Median duration of response |
13.6 months |
6.8 months | |
|
Deep response rate |
28.8% |
17.3% | |
|
OS hazard ratio |
0.58 |
Comparator arm | |
|
Safety |
Grade ≥3 treatment-emergent adverse events |
47.6% |
60.6% |
|
Grade ≥3 stomatitis |
2.2% | ||
Conclusion
The Phase III OptiTROP-Lung06 results highlight the potential of a TROP2-directed ADC plus immunotherapy to reshape first-line treatment for patients with PD-L1-negative advanced non-squamous NSCLC. Sac-TMT plus pembrolizumab more than doubled median PFS compared with chemotherapy plus pembrolizumab and prolonged response duration, despite similar ORRs. The lower incidence of grade 3 or higher treatment-emergent adverse events further supports the regimen’s potential clinical value. However, the immature OS findings and the need to assess longer-term safety and durability remain important considerations. If confirmed with further follow-up and supported by regulatory review, this chemotherapy-sparing strategy could offer a meaningful new option for a population with substantial unmet need.